QIAGEN announced it has entered into a definitive agreement to acquire Parse Biosciences, a pioneer in scalable, instrument-free single-cell sequencing solutions, marking a major expansion of QIAGEN’s Sample technologies portfolio into the rapidly growing single-cell and AI-powered genomics market. Parse’s proprietary Evercode combinatorial barcoding platform enables large-scale analysis of millions to billions of cells-supporting breakthroughs in health and disease research and fueling the data needed for AI-based drug discovery. The acquisition also strengthens QIAGEN Digital Insights (QDI) by enhancing customers’ ability to generate, process, and interpret large-scale, AI-driven single-cell datasets efficiently.
Also Read: JAS Announces the Acquisition of Pentagon Freight Services
“The addition of the Parse team to QIAGEN will significantly strengthen our offerings in one of the most dynamic areas of life science,” said Thierry Bernard, CEO of QIAGEN. “By combining Parse with our Sample technologies and bioinformatics expertise, we can empower researchers to create predictive virtual cell models that drive AI-based drug discovery.” Alex Rosenberg, CEO and co-founder of Parse Biosciences, added, “As our team joins QIAGEN, we want to accelerate our mission of making single-cell sequencing accessible to any lab worldwide.”